Is ASTH a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Astrana Health (ASTH) rests on The shift toward full-risk contracts: Astrana has been steadily moving members from shared-savings and partial-risk arrangements into full-risk capitation, which is what drove adjusted EBITDA up ~43% in Q2 2026 on ~49% revenue growth. The bear case rests on the core risk is structural: with operating margin of ~3.5%, a modest increase in medical cost trend or utilization can erase profitability across the capitated book, and 2023 through 2025 already showed net income falling from ~$60.7 million to ~$22.5 million even as revenue more than doubled. Analysts covering it publish targets from $45.00 to $65.00 against a $32.87 share price on November 16, 2026, so even the professionals disagree by 38% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
ASTH key stats
At $32.87 on November 16, 2026, Astrana Health (ASTH) has a market cap of $1.6B and a P/E of 30.4 on trailing earnings (9.0 on forward earnings).
- Market cap
- $1.6B
- P/E (trailing)
- 30.4
- P/E (forward)
- 9.0
- EPS (trailing 12 months)
- $1.08
- Price to book
- 1.9
- Beta
- 1.24
Market cap, P/E and yield are measured at the $32.87 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Astrana Health (ASTH)?
The last two weeks for Astrana Health, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- ASTH closed at $32.87 on November 16, 2026, down 2.7% over the past five trading days (from $33.77).
- On November 6, 2026, Astrana Health filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 5, 2026, Astrana Health filed an 8-K with the SEC reporting quarterly results and information shared with investors (Regulation FD) (Item 2.02, Item 7.01). Read the 8-K on sec.gov
- On November 6, 2026, Needham raised its target to $45.00 from $41.00 (Buy).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Astrana Health trades on Nasdaq under ASTH and was known as Apollo Medical Holdings (AMEH) until the 2024 rebrand. The company organizes independent physicians into risk-bearing networks and then contracts with health plans on a capitated basis, meaning it accepts a fixed per-member payment and keeps the difference if it can manage care for less. The business reports in three segments: Care Partners, the risk-bearing network arm that produces the large majority of revenue; Care Delivery, the owned and affiliated clinics; and Care Enablement, the technology and management-services platform that the networks run on. The membership base skews heavily toward Medicare Advantage, with Medicaid, commercial and ACO REACH or Medicare Shared Savings lives filling out the rest, and the geographic footprint is still concentrated in California even after expansion into Nevada, Texas and other states. Scale has arrived quickly. Revenue grew from ~$1.39 billion in fiscal 2023 to ~$3.18 billion in fiscal 2025 and ~$3.84 billion on a trailing twelve-month basis, helped substantially by the Prospect Health acquisition that closed in 2025 and added both membership and roughly $700 million of debt. Q2 2026, reported August 6, 2026, showed revenue of ~$972.5 million (up ~49%) and adjusted EBITDA of ~$68.9 million (up ~43%), and management raised full-year adjusted EBITDA guidance to ~$255 million to ~$280 million against reaffirmed revenue of ~$3.8 billion to ~$4.1 billion. Little of that revenue converts into profit: gross profit of ~$402 million on ~$3.84 billion of revenue is roughly a 10% gross margin, and operating margin is ~3.5%. In a capitated model almost all of that spread is medical cost, so utilization trend, not sales growth, is what decides the outcome. Since that report the stock has been volatile. As of October 16, 2026 it closed at ~$37.64, up ~49% year to date and ~18% over one year, but down ~17% over three months and well below the 52-week high of ~$51.60. Q2 EPS of ~$0.80 beat the ~$0.73 consensus, the fourth straight quarter above estimates, and GAAP quarterly earnings have climbed from ~$0.4 million in Q3 2025 to ~$19.7 million in Q2 2026. On October 10, 2026 AstranaCare Partners announced a multi-state partnership with Verda Healthcare covering Arizona and Texas, another step outside California. Q3 2026 results are scheduled for November 5, 2026, with consensus at ~$0.88 of EPS on ~$1.02 billion of revenue.
The bull case: what would have to be true for $65.00
The most optimistic published target on ASTH is $65.00, +97.7% from the $32.87 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. The shift toward full-risk contracts
Astrana has been steadily moving members from shared-savings and partial-risk arrangements into full-risk capitation, which is what drove adjusted EBITDA up ~43% in Q2 2026 on ~49% revenue growth. Full risk carries a larger economic share per member when care management works, so each converted cohort raises the ceiling on profitability. It also raises the floor risk, because the company absorbs cost overruns that a partial-risk contract would have shared with the health plan.
2. Membership growth through acquisition and network additions
The Prospect Health deal that closed in 2025 is the clearest example of the pattern: buy or affiliate physician groups, migrate them onto the Care Enablement platform, then move their contracts up the risk ladder. This has taken revenue from ~$1.39 billion in 2023 to ~$3.84 billion trailing. Whether it compounds depends on integration, because acquired groups arrive with their own cost curves and contract terms that take time to normalize. The October 2026 partnership between AstranaCare Partners and Verda Healthcare in Arizona and Texas follows the same playbook through affiliation rather than outright purchase.
3. Operating leverage on a fixed technology platform
Care Enablement is the piece meant to make additional members cheaper to serve, spreading platform and administrative cost across a wider base. Management's guidance for ~$105 million to ~$132.5 million of full-year 2026 free cash flow implies that leverage is starting to show up in cash rather than only in adjusted metrics. Trailing free cash flow of ~$94 million against ~$41 million of GAAP net income reflects the working-capital and non-cash-amortization gap typical of an acquisition-heavy roll-up.
4. Medicare Advantage rate and risk-model environment
Astrana's economics are set largely by CMS rate notices and by the phase-in of the v28 risk-adjustment model, which lowered coding-driven revenue across the Medicare Advantage industry. A more favorable rate cycle lifts the entire capitated cohort at once without any operational change, and an unfavorable one does the reverse. This is the single largest external variable in the model and it sits entirely outside company control.
The bear case: what would have to be true for $45.00
The most pessimistic published target is $45.00, +36.9% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Astrana Health is worth if the risks below bite instead of the drivers above.
The core risk is structural: with operating margin of ~3.5%, a modest increase in medical cost trend or utilization can erase profitability across the capitated book, and 2023 through 2025 already showed net income falling from ~$60.7 million to ~$22.5 million even as revenue more than doubled. Leverage compounds this, with total debt of ~$979 million against ~$401 million of cash after the Prospect transaction, so integration missteps land on a balance sheet with less slack than before. Concentration is real on two axes, geography (California remains the dominant market) and counterparty (a small number of health plans account for a large share of revenue, and contract renegotiation or non-renewal would be material). Regulatory exposure runs in several directions at once: CMS rate notices and the v28 risk-adjustment phase-in set the revenue baseline, federal scrutiny of Medicare Advantage risk-adjustment coding continues industry-wide, and California legislation targeting management-services organizations and the corporate practice of medicine could reach Astrana's structure directly. Separately, an employment class action alleging meal and rest period violations (Case No. 26STCV21467, Los Angeles County Superior Court) is pending against Astrana Health Management; it is a wage-and-hour matter rather than a securities case, and no filed securities-fraud class action was identified as of August 2026. The share price adds its own risk: a ~$18 to ~$52 52-week range shows how sharply sentiment swings on each cost-trend data point.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ASTH already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on ASTH
9 analysts cover ASTH, with an average target of $52.11 (+58.5% against $32.87) and a split of 10 buy, 1 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the ASTH forecast and price target page.
How is ASTH valued?
Market cap, P/E and dividend yield at today's price are in the ASTH key stats above. The business figures below come from Astrana Health's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$3.84B, latest quarter up ~49% year over year
- Margins: Gross ~10.5%, operating ~3.5%, net ~1.1%
- Net income (TTM): ~$40.6M, EPS ~$0.83
- Most recent quarter (Q2 2026): Revenue ~$972.5M, EPS ~$0.80 vs ~$0.73 estimate
- Balance sheet: ~$979M total debt against ~$401M cash
- Dividend: None
As of October 2026: The gap between a ~45x trailing multiple and a ~10x forward multiple is the whole debate in one number: analysts expect EPS of ~$3.07 for 2026 and ~$3.64 for 2027, against ~$0.83 of trailing GAAP EPS, so the price assumes the adjusted EBITDA guidance converts into GAAP earnings. Market cap of ~$1.87 billion is about half of trailing revenue (P/S ~0.49), which is normal for capitated healthcare because the company books the full premium dollar as revenue while keeping a thin slice. Margin and cash conversion are the relevant lenses, and the November 5 Q3 report is the next test.
How do you decide if ASTH is a buy?
Whether ASTH is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ASTH indirectly through an index or sector ETF before adding more.
What would change your mind on ASTH
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: The shift toward full-risk contracts stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: the core risk is structural: with operating margin of ~3.5%, a modest increase in medical cost trend or utilization can erase profitability across the capitated book, and 2023 through 2025 already showed net income falling from ~$60.7 million to ~$22.5 million even as revenue more than doubled fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the ASTH stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ASTH against your real portfolio and see your actual exposure before deciding.
Your questions about Astrana Health
Ask Walnut's AI anything about ASTH and see how it fits what you own.
FAQ
Is ASTH a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on The shift toward full-risk contracts, with revenue (ttm) at ~$3.84B, latest quarter up ~49% year over year. The bear case rests on the core risk is structural: with operating margin of ~3.5%, a modest increase in medical cost trend or utilization can erase profitability across the capitated book, and 2023 through 2025 already showed net income falling from ~$60.7 million to ~$22.5 million even as revenue more than doubled. Analysts covering it are spread from $45.00 to $65.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell ASTH?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The core risk is structural: with operating margin of ~3.5%, a modest increase in medical cost trend or utilization can erase profitability across the capitated book, and 2023 through 2025 already showed net income falling from ~$60.7 million to ~$22.5 million even as revenue more than doubled. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $45.00, +36.9% from the $32.87 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for ASTH?
+
The shift toward full-risk contracts. Astrana has been steadily moving members from shared-savings and partial-risk arrangements into full-risk capitation, which is what drove adjusted EBITDA up ~43% in Q2 2026 on ~49% revenue growth. The most optimistic analyst target on ASTH is $65.00, +97.7% from the $32.87 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for ASTH?
+
The core risk is structural: with operating margin of ~3.5%, a modest increase in medical cost trend or utilization can erase profitability across the capitated book, and 2023 through 2025 already showed net income falling from ~$60.7 million to ~$22.5 million even as revenue more than doubled. Leverage compounds this, with total debt of ~$979 million against ~$401 million of cash after the Prospect transaction, so integration missteps land on a balance sheet with less slack than before. Concentration is real on two axes, geography (California remains the dominant market) and counterparty (a small number of health plans account for a large share of revenue, and contract renegotiation or non-renewal would be material). Regulatory exposure runs in several directions at once: CMS rate notices and the v28 risk-adjustment phase-in set the revenue baseline, federal scrutiny of Medicare Advantage risk-adjustment coding continues industry-wide, and California legislation targeting management-services organizations and the corporate practice of medicine could reach Astrana's structure directly. Separately, an employment class action alleging meal and rest period violations (Case No. 26STCV21467, Los Angeles County Superior Court) is pending against Astrana Health Management; it is a wage-and-hour matter rather than a securities case, and no filed securities-fraud class action was identified as of August 2026. The share price adds its own risk: a ~$18 to ~$52 52-week range shows how sharply sentiment swings on each cost-trend data point. The most pessimistic published target is $45.00, +36.9% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Astrana Health do?
+
Astrana Health is a physician-centric value-based care company that organizes independent doctors into risk-bearing networks and takes capitated payments from health plans.
What would have to change for ASTH to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The shift toward full-risk contracts) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the core risk is structural: with operating margin of ~3.5%, a modest increase in medical cost trend or utilization can erase profitability across the capitated book, and 2023 through 2025 already showed net income falling from ~$60.7 million to ~$22.5 million even as revenue more than doubled) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What company is ASTH?
+
ASTH is Astrana Health, Inc., a Nasdaq-listed, physician-centric value-based healthcare company headquartered in California. It organizes independent physicians into risk-bearing networks and contracts with health plans on a capitated basis, primarily serving Medicare Advantage and Medicaid members.
Was ASTH formerly Apollo Medical Holdings (AMEH)?
+
Yes. The company traded as Apollo Medical Holdings under the ticker AMEH before rebranding to Astrana Health in 2024, at which point the ticker changed to ASTH. It is the same operating business with the same corporate history, not a new listing.
Is Astrana Health profitable?
+
Yes, on a GAAP basis, which distinguishes it from several value-based care peers. Trailing twelve-month net income as of October 2026 is ~$40.6 million on ~$3.84 billion of revenue, or roughly a 1% net margin, and quarterly GAAP earnings have risen from ~$0.4 million in Q3 2025 to ~$19.7 million in Q2 2026. The profitability is real but very thin relative to revenue.
Walnut is informational, not investment advice, and gives no verdict on ASTH. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.